The immunogenetics of viral antigen response is associated with sub-type specific glioma risk and survival

3

Geno Guerra, Ph.D.,^{1,*} Linda Kachuri, Ph.D.,² George Wendt, B.A.,¹ Helen M. Hansen, B.A.,¹
Steven J. Mack, Ph.D.,³ Annette M. Molinaro, Ph.D.,^{1,2} Terri Rice, M.P.H.,¹ Paige Bracci, Ph.D.,²
John K. Wiencke, Ph.D.,^{1,2,4} Nori Kasahara, M.D, Ph.D.,^{1,7} Jeanette E Eckel-Passow, Ph.D.,⁵
Robert B. Jenkins, M.D., Ph.D.,⁶ Margaret Wrensch, Ph.D.,^{1,4} Stephen S. Francis, Ph.D.,^{1,2,7,**}

- 9 1. Department of Neurological Surgery, University of California San Francisco, San Francisco, CA,
- 10 USA
- 11 2. Department of Epidemiology and Biostatistics, University of California San Francisco, San
- 12 Francisco, CA, USA
- 13 3. Department of Pediatrics, University of California, San Francisco, Oakland, California, USA
- 14 4. Institute of Human Genetics, University of California San Francisco, San Francisco, California
- 15 5. Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA
- 16 6. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
- 17 7. Weill Institute for Neurosciences, University of California San Francisco, San Francisco, USA
- 18 * Corresponding author: <u>geno.guerra@ucsf.edu</u>
- 19 ** Corresponding author: <u>stephen.francis@ucsf.edu</u>

It is made available under a CC-BY-NC-ND 4.0 International license .

20 Abstract

Glioma is a highly fatal cancer with prognostically significant molecular subtypes and few known risk factors. Multiple studies have implicated infections in glioma susceptibility, but evidence remains inconsistent. Genetic variants in the human leukocyte antigen (HLA) region modulate host response to infection and have been linked to glioma risk. In this study we leveraged genetic predictors of antibody response to 10 viral antigens to investigate the relationship with glioma risk and survival.

Genetic reactivity scores (GRS) for each antigen were derived from genome-wide significant (p<5×10⁻⁸) variants associated with immunoglobulin G antibody response in the UK Biobank cohort. We conducted parallel analyses of glioma risk and survival for each GRS and HLA alleles imputed at two-field resolution using data from 3418 glioma patients subtyped by somatic mutations and 8156 controls.

Genetic reactivity scores to Epstein-Barr virus (EBV) ZEBRA and EBNA antigens and Merkel cell polyomavirus (MCV) VP1 antigen were associated with glioma risk and survival (Bonferronicorrected p<0.01). GRS_{ZEBRA} and GRS_{MCV} were associated in opposite directions with risk of *IDH* wild type gliomas (OR_{ZEBRA}=0.91, p=0.0099 / OR_{MCV}=1.11, p=0.0054). GRS_{EBNA} was associated with both increased risk for *IDH* mutated gliomas (OR=1.09, p=0.040) and improved survival (HR=0.86, p=0.010). *HLA-DQA1*03:01* was significantly associated with decreased risk of glioma overall (OR=0.85, p=3.96x10⁻⁴) after multiple testing adjustment.

39 This first systematic investigation of the role of genetic determinants of viral antigen reactivity in 40 glioma risk and survival provides insight into complex immunogenomic mechanisms of glioma 41 pathogenesis. These results may inform applications of antiviral based therapies in glioma 42 treatment.

43

It is made available under a CC-BY-NC-ND 4.0 International license .

44 Keywords

- 45 Glioma, human leukocyte antigen, Epstein-Barr virus, Merkel cell polyomavirus, polygenic risk
- 46 score
- 47
- 48
- 49
- 50

It is made available under a CC-BY-NC-ND 4.0 International license .

51 Introduction

52

Studies linking viruses and cancer date back over 100 years¹ and laid the foundation for 53 54 understanding oncogenes². It has also become increasingly clear, as well evidenced by the 55 current pandemic, that host genetics play an important role in response to viruses^{3,4}. To date, 56 seven viruses have been accepted to be tumor-initiating in humans; Epstein-Barr virus (EBV). 57 hepatitis B virus (HBV), human papillomavirus (HPV), human T-lymphotropic virus-1 (HTLV-1), 58 hepatitis C (HCV), Kaposi's sarcoma herpesvirus (HHV-8) and Merkel cell polyomavirus (MCV)⁵. 59 Recent analyses have shown that infections account for approximately 13% of human cancers 60 worldwide⁶. However viruses have not been definitively implicated in the etiology of glioma despite decades of suggestive associations⁷⁻¹¹. 61

62

63 Glioma is a highly fatal brain cancer with a paucity of known risk factors, with exposure to ionizing radiation being the accepted causal factor¹². A history of previous infection with Varicella-64 65 Zoster virus (VZV) has been the only infectious agent consistently linked to adult glioma. conferring an estimated 20% decrease in risk^{10,13}. A suite of other viruses have been associated 66 67 with the risk and grade of glioma, including EBV, MCV, John Cunningham virus (JCV), BK virus 68 (BKV), human Cytomegalovirus (CMV) and human herpesvirus-6 (HHV-6), but with discordant 69 results^{11,14–16}. The identification of key somatic molecular alterations (e.g. *IDH* mutation, 1p/19g 70 chromosomal arm codeletion, TERT mutation), which drastically affect glioma prognosis, have uncovered subtype-specific risk factors^{17,18}. Recently, several studies/clinical trials have 71 suggested a prognostic benefit of antiviral medications in the treatment of alioma¹⁹⁻²¹. 72

73

It is made available under a CC-BY-NC-ND 4.0 International license .

74 Genetic host response to viral infection could play a role in elucidating potential links 75 between viruses and cancer incidence and prognosis. Studies have demonstrated significant 76 heritable components (32-48%) of antibody response to many viruses and have identified genetic 77 loci within host genes related to cell entry, cytokine production, and immune response²²⁻²⁴. 78 Genetic variants of class I and II human leukocyte antigen (HLA) genes contribute the most 79 important identified components of genetic determinants of response to viral antigens. Class II 80 genes each encode half of a heterodimeric class II HLA protein, which presents extra-cellularly-81 derived peptides to CD4+ helper T-cells. The immune response is triggered when a CD4+ T-cell 82 recognizes the combination of a call II HLA protein and its bound peptide. It is well studied that CD4+ T-cells have an important role in creating and sustaining effective anti-tumor immunity²⁵. 83

84

The HLA region of the genome is considered the most polymorphic region of the human genetic system²⁶ where polymorphisms have been shown to alter the risk and progression of disease in a variety of autoimmune (notably HLA class II) and malignant conditions^{27,28}. Certain HLA haplotypes have shown non-additive epistatic effects on glioma risk²⁹, yet no germline variants within the HLA have been directly identified as risk loci in a glioma GWAS.

90

In this study we leveraged previously published genome-wide SNP associations with viral antibody response³⁰ to generate genetically inferred antigen reactivity profiles in glioma cases and controls and evaluated their association with risk and survival by major glioma subtypes. We further conducted imputed HLA gene association analysis with glioma risk and survival and our findings suggest a convergence of genetic mechanisms regulating host immune response to viral challenge and glioma development and progression.

97

98 Methods

It is made available under a CC-BY-NC-ND 4.0 International license .

100 Ethics

101

102	Collection of patient samples and associated clinicopathological information was
103	undertaken with written informed consent and relevant ethical review board approval at the
104	respective study centers in accordance with the tenets of the Declaration of
105	Helsinki. Specifically informed consent and ethical board approval was obtained from the UCSF
106	Committee on Human Research (USA) and the Mayo Clinic Office for Human Research
107	Protection (USA). The diagnosis of glioma (ICDO-3 codes 9380-9480 or equivalent) was
108	established through histology in all cases in accordance with World Health Organization
109	guidelines.
110	
111	Study Populations
112	
113	We analyzed three glioma case-control sets assembled based on genotyping platform and

114 study population for a total sample size of 3418 cases and 8156 controls (Figure 1, Table 1). The 115 first set included 1973 cases from the Mayo Clinic and University of California, San Francisco 116 (UCSF) Adult Glioma Study and 1859 controls from the Glioma International Case-Control Study (GICC) who were genotyped on the Illumina OncoArray, as previously described^{18,31-34}. The 117 118 second dataset included 659 cases and 586 controls from the UCSF Adult Glioma study 119 genotyped on the Illumina HumanHap370duo panel³². The third dataset included 786 glioma 120 cases from The Cancer Genome Atlas (TCGA) with available molecular data genotyped on the 121 Affymetrix 6.0 array. Cancer-free controls were assembled from two Wellcome Trust Case Control 122 Consortium (WTCCC) studies genotyped using the Affymetrix 6.0 array: 2,917 controls from the 123 1958 British Birth cohort and 2,794 controls from the UK Blood Service control group.

It is made available under a CC-BY-NC-ND 4.0 International license .

124 Molecular subtype information (IDH mutation and 1p/19g codeletion status) was downloaded from

125 Ceccarelli et al.³⁵ supplementary table 1 for the third dataset and was provided directly from the

126 UCSF AGS study and Mayo Clinic for the first and second datasets.

127

128 **Quality Control and Imputation**

129

130 Standard quality control procedures were implemented prior to imputation. Analyses were 131 predominantly (>70%) European ancestry, determined using restricted to individuals of 132 ADMIXTURE³⁶ and the HapMap 3 reference populations. Within each ancestral group, we 133 removed samples with excess heterozygosity (>3 standard deviations (SD) from mean), <95% 134 call rates, and discordant self-reported and genetically inferred sex. Relatedness checks were performed within each study using KING³⁷ (kinship >0.12), filtering out up to second-degree 135 136 relations and retaining the samples with higher call rate. TCGA blood samples were preferentially 137 chosen when both blood and tumor sequencing data were available for the same patient (693 138 European samples had both blood and tumor samples available). SNPs with <95% call rate were 139 removed, along with variants deviating from Hardy-Weinberg equilibrium (p<10⁻⁶) or at a low minor 140 allele frequency (MAF<0.005). Samples genotyped on the same platform (i.e., Affymetrix 6.0 for 141 TCGA and WTCCC) were imputed together using the multi-ethnic TOPMed reference panel (ver. 142 r2).

- 143
- 144 Statistical Analysis
- 145
- 146 Genetically Predicted Viral Antigen Response
- 147

It is made available under a CC-BY-NC-ND 4.0 International license .

148	Genetic seroreactivity scores (GRS) were calculated to obtain genetically inferred viral					
149	antigen response profiles in each of the glioma datasets. For each GRS, candidate variants and					
150	corresponding effect sizes were obtained from genome-wide summary statistics for seroreactivity					
151	to 10 viral antigens previously identified in Kachuri and Francis et al. 2020 ³⁰ in 7895 randomly					
152	selected individuals of European descent from the UK Biobank (UKB) cohort using serological					
153	measures. For each antigen, we preferentially selected independent SNPs (linkage					
154	disequilibrium, LD, r ² <0.01 within 500kb) with the lowest p-value among genome-wide significant					
155	variants ($p < 5x10^{-8}$). LD proxies ($r^2 > 0.9$) were obtained for variants unavailable in the target glioma					
156	datasets. For each individual, an antigen-specific GRS was calculated as a weighted sum with					
157	weights (β) corresponding to a standard deviation increase in antibody response:					
158	$GRS_{Antigen} = \beta_1 x SNP_1 + + \beta_k x SNP_k$					
159	Each GRS was calculated using a minimum of 4 variants with MAF>=0.01 and imputation quality					
160	(R ² >0.6), and then standardized within each dataset.					
161						
162	Antigen GRS Associations with Glioma Susceptibility					
163						
164	GRS associations with disease risk were examined for glioma overall and for molecular					
165	subtypes defined by the specific tumor alterations: IDH mutation status and 1p/19q chromosomal					
166	arm codeletion. For each GRS, odds ratios (OR) were estimated using logistic regression models					
167	adjusted for age, sex, and the first 10 genetic ancestry principal components (PCs). Models in the					
168	UCSF-Mayo dataset were further adjusted for contributing site. GRS associations from each study					
169	were meta-analyzed using a fixed-effects inverse-variance weighted approach. Heterogeneity in					
170	study-specific GRS associations was assessed using Cochran's Q test.					
171						

172 Antigen GRS Associations with Glioma Survival

It is made available under a CC-BY-NC-ND 4.0 International license .

1	.7	3

174 The association between each antigen-GRS and overall survival was assessed using a 175 Cox proportional hazards regression model with follow-up time calculated from the date of first 176 surgery to either date of death or last known contact. The latter censored at that date. Analyses 177 were conducted for glioma overall and molecular subtypes with a minimum of 50 cases and 20 178 events (deaths). Proportionality assumptions were checked within each dataset via examination 179 of Kaplan-Meier curves. Hazard ratios (HR) were estimated using Cox models adjusted for age, 180 sex, 10 genetic PCs, and study site (if applicable). Associations with survival in each study were 181 combined using fixed-effects meta-analysis. For each nominally significant (p<0.05) glioma-GRS 182 association, survival differences were further assessed using Kaplan-Meier curves by comparing 183 mortality trajectories in patients with high genetically predicted immune reactivity (top 20%) to the 184 remainder.

185

186 Regional HLA Analyses of glioma risk and survival

187

188 Classical HLA alleles were imputed for samples in all cohorts at two-field resolution using 189 SNP2HLA³⁸ and the Type 1 Diabetes Genetics Consortium (T1DGC) reference panel of 2,767 190 unrelated individuals. Associations were tested for 77 alleles (MAF>=0.01) with imputation quality 191 >0.4 across eight genes: *HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-*192 *DQB1, HLA-DRB1*.

193

Subtype-specific associations with risk were estimated using logistic regression models.
 HLA allele associations with mortality were assessed using SPACox³⁹, an extension of the Cox
 model with improved type I error control in high-dimensional settings. Study-specific risk and

It is made available under a CC-BY-NC-ND 4.0 International license .

- 197 survival associations were combined in a meta-analysis. Associations for each HLA allele were 198 considered statistically significant if $p < 6.5 \times 10^{-4}$ (0.05/77 alleles).
- 199
- 200 **Results**
- 201

202 The creation of a GRS was attempted for all antigens with genome-wide significant 203 seroreactivity-associated variants (p<5x10⁻⁸) as reported in Kachuri and Francis et al. 2020³⁰. This 204 included 10 antigens: Four EBV antigens (EA-D, EBNA, p18, ZEBRA) and antigens for BKV, 205 HHV7, HSV1, JCV, MCV, and VZV. We do not include antigens for CMV and HHV6 in our study 206 as there was only one significantly associated SNP each in the previously published GWAS. An 207 antigen-specific GRS was considered successfully created if at least four independent SNPs 208 passed LD clumping and thresholding and were present (or via proxy SNP) in the three glioma 209 study datasets. GRS were successfully generated for EBV EA-D, EBV EBNA, EBV p18, EBV 210 ZEBRA, and MCV. Only one independent SNP remained for each of HSV1, BKV, JCV and VZV 211 after accounting for long-range LD in the HLA region, although having numerous SNPs meet 212 genome-wide significance in the previous seroreactivity study. Three SNPS remained for HHV7, 213 each on a different chromosome (6.11, and 17). Complete information of variants considered for 214 all 12 viral antigens, including nearest gene and corresponding glioma risk associations are 215 reported in Supplement Tables S1 and S2. LD correlations for all associated chromosome 6 216 variants are available in a heatmap in Supplement Figure S1.

217

The variants included in each of the five created GRSs were overwhelmingly located in the HLA region, with few predictors located elsewhere across the genome: rs67886110 in 3q25.1 an eQTL for *MED12L* and *P2RY12* (EBV EBNA), rs7618405 in 3p24.3 (MCV), and rs7444313 in 5q31.2 near *TMEM173* (MCV). Of the 38 SNPs included across the 5 GRSs, 2 had a significant

It is made available under a CC-BY-NC-ND 4.0 International license .

association (Bonferroni-corrected: $p<1.3x10^{-3}$) with overall glioma risk: rs9265517 near *HLA-B* (EBV EBNA), p=3.08x10⁻⁴ and rs9268847 near *HLA-DRB9* (MCV), p=2.86x10⁻⁴. **Supplement Table S2** visualizes the squared correlation between the GRS SNPs and each imputed HLA allele (two field resolution) from UCSF-Mayo cases and controls. Notably, the GRS for MCV was inversely correlated with GRSs for EBV ZEBRA (Pearson's r=-0.28, p=3.89x10⁻⁷⁰) and EBV EBNA (r=-0.19, p=6.28x10⁻³¹) (Figure 2).

228

- 229 Viral antigen GRS associations with glioma risk
- 230

231 In the combined meta-analysis of three case-control studies, three GRS's reached at least 232 nominal significance (p<0.05), with some associations remaining statistically significant after 233 correction for the number of antigens tested (Bonferroni: p=0.05/5=0.01) (Figure 3). Genetic 234 predisposition to an increased serological response to EBV ZEBRA was inversely associated with 235 risk of glioma overall (per 1 SD increase in GRS: Odds Ratio, OR_{ZEBRA}=0.94, 95% confidence 236 interval 0.89-0.99, p=0.012, 3418 cases). GRS_{EBNA} was associated with an increased risk of IDH 237 mutated gliomas (OR_{EBNA}=1.09,1.004-1.18, p=0.040, 1074 cases) and the magnitude of this effect 238 increased for IDH mutated 1p/19g codeleted gliomas (OR_{EBNA}=1.14, 1.012-1.28, p=0.031, 396 239 cases).

240

We observed some evidence of antagonistic pleiotropy between genetic determinants of antibody response to EBV ZEBRA and MCV, which generalized across glioma subtypes. GRS_{ZEBRA} and GRS_{MCV} were associated with susceptibility to *IDH* wild type gliomas, but in opposite directions: Higher genetically predicted reactivity to EBV ZEBRA was inversely associated with *IDH* wild type glioma risk (OR_{ZEBRA}=0.91, 0.85-0.98, p=0.0072, 1479 cases), while increased predicted antibody response to MCV conferred an increased risk (OR_{MCV}=1.09, 1.02-

247	1.17, p=0.013). This pattern persisted for IDH wild type 1p/19q non-codeleted gliomas
248	$(OR_{ZEBRA}=0.91, 0.84-0.9, p=0.0099; OR_{MCV}=1.11, 1.03-1.19, p=0.0054, 1280$ cases). The
249	correlation between GRS _{ZEBRA} and GRS _{MCV} (Pearson's r=-0.28, p= 3.9×10^{-70} in UCSF-Mayo,
250	Figure 2) suggests a possible shared underlying genetic mechanism between the response to
251	the two antigens. GRS_{ZEBRA} and GRS_{MCV} were tested together, along with interaction term, in a
252	single logistic model and we observed no significant interaction (p=0.34 in <i>IDH</i> wild type risk).
253	
254	Viral antigen GRS-survival associations
255	
256	The number of available cases and deaths across the three studies is available in Table
257	2. Associations between genetically predicted viral antigen response profiles and survival were
258	restricted to IDH mutated gliomas (Figure 4). GRS _{EBNA} was associated with survival in 1074 IDH
259	mutated glioma cases (per 1 SD increase: Hazard Ratio, HR=0.86, 0.76-0.96, p=0.010, 325
260	events), suggesting that a higher genetically predicted reactivity to EBV EBNA improved duration
261	of survival.
262	
263	GRS for two EBV antigens were nominally associated with survival amongst 244 IDH
264	mutated 1p/19q codeleted glioma cases, but in opposite directions (HR _{EBNA} =0.75, 0.57-0.99
265	p=0.048 / HR _{ZEBRA} =1.27,1.01-1.6, p=0.042, 64 events). This subtype-specific result was limited to
266	the UCSF-Mayo dataset due to insufficient number of reported events (deaths) in IDH mutated
267	1p/19q codeleted glioma cases from TCGA and AGS-i370.
268	
269	GRS _{EBNA} was also associated with improved survival outcomes in 614 <i>IDH</i> mutated 1p/19q
270	non-codeleted glioma cases (HR=0.75, 0.74-0.997, p=0.045, 222 events), suggesting the

It is made available under a CC-BY-NC-ND 4.0 International license .

association of GRS_{EBNA} is independent of 1p/19q status. Figure 5 visualizes the significant
 GRS_{EBNA} associations using Kaplan-Meier survival curves.

273

We did not detect any significant GRS associations in the analysis of glioma overall, which is consistent with the strong prognostic significance of molecular glioma subtypes^{17,33}. Also, as the prognosis in *IDH* wild type gliomas is the poorest, we suspect our GRS instruments are underpowered to detect significant deviations over such short intervals. Full survival results are available in **Supplement Figures S3 and S4**.

279

280 HLA allele-glioma associations

281

282 Of the 77 HLA alleles imputed at two-field resolution, only HLA-DQA1*03:01 reached 283 Bonferroni-corrected significance ($p<6.5x10^{-4}$ after correcting for 77 HLA alleles tested) for 284 association with glioma risk in a meta-analysis. The presence of an HLA-DQA1*03:01 allele was 285 associated with a decrease in overall glioma risk (OR=0.85, p=3.96x10⁻⁴). This allele was also 286 nominally associated with risk of IDH wild type (OR=0.82, p=1.4x10⁻³) and IDH wild type 1p/19g 287 non-codeleted gliomas (OR=0.81, p=2.6x10⁻³). These subtype-specific associations and direction 288 of effect mirror those of GRS_{ZEBRA} presented above, suggesting HLA-DQA1*03:01 as a potential 289 shared marker for both glioma risk and EBV ZEBRA seroreactivity. Results of all HLA allele (one 290 and two field resolution) associations with glioma risk tested in a meta-analysis are available in 291 Supplement Table S2.

292

293 **Discussion**

294

It is made available under a CC-BY-NC-ND 4.0 International license .

We investigated genetically predicted antibody response to ten antigens for seven viruses in relation to glioma risk and prognosis in a meta-analysis of three patient cohorts with molecular subtype information. Our analysis discovered evidence that genetic predisposition to reactivity to specific viral antigens associated with susceptibility to glioma in a subtype-specific manner. This pattern of effect modification by glioma subtype also extends into prognosis, where we observed associations between viral antigen GRSs and survival among specific glioma subtypes.

301 One of our main findings is that genetic predisposition to increased seroreactivity to EBV 302 ZEBRA was associated with a decreased overall glioma risk, with a significant decrease in IDH 303 wild type subtypes. Predicted reactivity to the MCV VP1 antigen mirrored the same IDH wild type 304 associations but in the opposite direction, where higher reactivity was associated with increased 305 glioma risk. The significant inverse relationship between predicted reactivity to EBV ZEBRA and 306 MCV VP1 highlights the possibility of shared genetic components of antibody response to the two 307 antigens. Understanding the underlying mechanisms guided by these genetics is left as an open 308 question. A possible link is that the class II HLA allele DQA1*03:01 was associated with decreased 309 glioma risk in the same subtypes associated with GRSs for EBV ZEBRA. In our previous UKB 310 analysis³⁰ the presence of HLA-DQA1*03:01 was positively associated with EBV ZEBRA 311 seroreactivity measurements (β =0.168, p=1.3x10⁻¹⁶). Taken together, the associations between 312 HLA-DQA1*03:01, EBV ZEBRA and glioma risk suggest possible shared underlying 313 immunogenetic architecture. As HLA class II proteins present potentially antigenic peptides, 314 functional genetic alterations can result in changes to the binding affinity of specific antigens, 315 modulating the potential for recognition by CD4+ helper T-cells. It is possible that the 316 heterodimeric DQ proteins half-encoded by DQA1*03:01 have improved binding or recognition of 317 peptides presented by both EBV ZEBRA proteins and glioma (specifically IDH wild type), allowing 318 for an increased immune response in both cases. As IDH wild type has generally been shown to 319 serve as a marker for more severe glioma cases, the exact somatic tumor alterations leading to 320 recognized peptide variants in these tumors is not clear and is an area that warrants future

It is made available under a CC-BY-NC-ND 4.0 International license .

investigation. Further analysis of viral-tumor protein homology is needed to understand if thiscould be a possible connection.

323

324 Interestingly, a higher genetically predicted response to EBV EBNA was nominally 325 associated with increased risk in IDH mutated/1p/19g codeleted gliomas. Still, reactivity towards 326 EBV EBNA was more strongly associated with improved survival in *IDH* mutated gliomas. This 327 discrepancy between the disease-promoting and pro-survival associations of GRS_{EBNA} may 328 suggest the presence of different biologic pathways after initiation of disease. It may also point 329 towards EBV latency-mediated treatment effects. Previous studies show that the EBV latency 330 type predicts the relative amount of induced reactivation generated by cytotoxic chemotherapy 331 drugs⁴⁰. Therefore, individuals who react strongly to EBV EBNA antigens may exhibit a different 332 pattern of reactivation when treated with temozolomide. Further research is required to elucidate 333 this putative association, yet it is clear that EBV lytic/latent cycling is a critical aspect of other 334 germline interactions and disease risk.

335

Epstein-Barr virus was the first recognized human oncovirus⁴¹ and exists in two distinct 336 337 life cycles within a host: a lytic phase of active infection where new viruses are produced, and a 338 latent phase where the virus remains dormant to avoid detection by the host. Distinct sets of 339 antigens are produced during these two phases, two of such are EBNA, during the latent phase 340 of infection, and the ZEBRA protein which initiates a change from latent to lytic gene expression. 341 Past evidence suggests processes during the latent stage are responsible for the virus' oncogenic 342 properties via mechanisms promoting cell growth and preventing cell apoptosis (reviewed in 343 Akhtar et al. 2018⁴²). Recent work has also implicated the ZEBRA protein as oncogenic with 344 evidence demonstrating its ability to deregulate immune surveillance and promote immune $escape^{43}$. 345

346

It is made available under a CC-BY-NC-ND 4.0 International license .

In contrast MCV is the most recently recognized human oncovirus, first described in 2008 and later accepted as a causal agent for Merkel cell carcinoma⁴⁴, a neuroendocrine carcinoma. Previous studies have identified the presence of MCV DNA in glioma patients and have drawn an association with infection and increased risk of glioma^{15,16}. It has been shown that both the large T and small T antigens of MCV are oncoproteins that target tumor suppressor proteins such as pRB. Although the exact latency mechanism in polyomaviruses is unknown, it has been suggested that complex protein-mediated latency may be critical to the MCV lifecycle⁴⁵.

354

355 In interpreting our findings, several limitations should be acknowledged. The shared 356 genetic architecture between the viruses studied here, as seen in the correlations in Figure 2 and 357 Supplement Figure S1, may result in a lack of specificity. This limitation in our study may be 358 applicable in other viruses that share the same underlying genetic programming of antigen 359 response, particularly VZV, which is associated with a unique pattern of LD spanning a large 360 region of the HLA³⁰. Furthermore, the clumping and thresholding approach to GRS development 361 may not be optimal for regions with complex LD structure, such as HLA. An approach that can 362 appropriately account for the long-range correlation structure and capture non-linear interactions, 363 such as haplotype effects, may improve future studies that use genetically inferred immune 364 responses. Another challenge is the low SNP density in the HLA region in the present study, as 365 well as reliance on imputed HLA alleles both in the glioma studies and in UKB. The HLA region 366 is highly polymorphic and imputation of alleles from SNP data is limiting and prone to error. 367 Similarly, it is difficult to disentangle the specific function of SNPs located in the HLA region. As 368 such, additional studies leveraging HLA sequencing approaches are required to provide further 369 granularity of the genetic determinants of antigen response and glioma risk/survival.

Additionally, we could not study the relationship between reactivity to several antigens of interest (BKV, HSV-1, JCV, VZV, HHV-7, HHV-6, CMV) due to the limited number of variants reaching genome-wide significance and/or meeting our GRS criteria³⁰. Although the GRS-glioma

It is made available under a CC-BY-NC-ND 4.0 International license .

373 association results presented here require further replication in independent patient populations,

374 our findings are intriguing and suggest previous inconsistencies in observational epidemiologic

375 may be partially due to individual differences in genetic factors that affect antigen reactivity.

This is the first study directly examining the underlying genetic architecture of antigen reactivity to common viruses and glioma risk and survival. We observed important associations between programmed reactivity to viruses and glioma etiology and prognosis. This methodology is not limited to the study of glioma, as the GRS instruments proposed here can readily be applied to cohorts of any cancer type. This offers a unique approach for future studies to reinvestigate the genetic contributions of long-running epidemiologic associations between viruses and cancer, and possibly clarify effects of viral therapies in their treatment.

383

384 Supplemental Information

385 Supplemental data include five tables and five figures.

386

387 Funding and Acknowledgments

388 Work at University of California, San Francisco was supported by the National Institutes 389 of Health (grant numbers T32CA151022, R01CA52689, P50CA097257, R01CA126831, 390 R01CA139020, R01AI128775, and R25CA112355), the National Brain Tumor Foundation, 391 the Stanley D. Lewis and Virginia S. Lewis Endowed Chair in Brain Tumor Research, the Robert 392 Magnin Newman Endowed Chair in Neuro-oncology, and by donations from families and friends 393 of John Berardi, Helen Glaser, Elvera Olsen, Raymond E. Cooper, and William Martinusen. 394 This publication was supported by the National Center for Research Resources and the National 395 Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI 396 Grant Number UL1 RR024131. Its contents are solely the responsibility of the authors and do not

397 necessarily represent the official views of the NIH.

It is made available under a CC-BY-NC-ND 4.0 International license .

398

399 The collection of cancer incidence data used in this study was supported by the California 400 Department of Public Health pursuant to California Health and Safety Code Section 103885: 401 Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries, 402 under cooperative agreement 5NU58DP006344; the National Cancer Institute's Surveillance, 403 Epidemiology and End Results Program under contract HHSN261201800032I awarded to the 404 University of California, San Francisco, contract HHSN261201800015I awarded to the University 405 of Southern California, and contract HHSN261201800009I awarded to the Public Health Institute, 406 Cancer Registry of Greater California. The ideas and opinions expressed herein are those of the 407 author(s) and do not necessarily reflect the opinions of the State of California, Department of 408 Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention 409 or their Contractors and Subcontractors.

410

411 Data Availability

Genotype data of control samples from the 1958 British Birth Cohort and UK Blood Service Control Group were made available from the Wellcome Trust Case Control Consortium (WTCCC) and downloaded from the European Genotype Archive under ascension numbers <u>EGAD0000000021</u> and <u>EGAD0000000023</u>, respectively. Genotype data of glioma cases from The Cancer Genome Atlas (TCGA) were obtained from Database of Genotypes and Phenotypes (dbGaP) (phs000178). Genotype data of control samples from the Glioma International Case Control Study (GICC) are available from dbGaP under accession <u>phs001319.v1.p1</u>.

419 Notes

420 **Declaration of interests**

421 The authors declare no competing interests.

It is made available under a CC-BY-NC-ND 4.0 International license .

422 Authorship

- 423 GG, LK, and SSF conceived of the study and wrote main drafts of the manuscript. GG,
- 424 LK, GW, SJM, NK, and SSF conducted and advised on informatic and statistical analyses along
- 425 with result interpretations. HMH, AMM, TR, PB, JKW, JEE, RBJ, and MW were involved in primary
- 426 data collection. All authors contributed and reviewed the final manuscript.

427

It is made available under a CC-BY-NC-ND 4.0 International license .

428 **References**

- Rous P. A Tranimissible Avian Neoplasm. (Sarcoma of the common fowl.). *J Exp Med*.
 1910;12(5):696-705. doi:10.1084/jem.12.5.696
- 431 2. Duesberg PH, Vogt PK. Differences between the ribonucleic acids of transforming and
- 432 nontransforming avian tumor viruses. *Proc Natl Acad Sci U S A*. 1970;67(4):1673-1680.
- 433 doi:10.1073/pnas.67.4.1673
- 434 3. COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19.
 435 *Nature*. Published online July 8, 2021. doi:10.1038/s41586-021-03767-x
- 436 4. Sudlow C, Gallacher J, Allen N, et al. UK Biobank: An Open Access Resource for Identifying
 437 the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PLOS Med*.
 438 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779
- 439 5. Mui UN, Haley CT, Tyring SK. Viral Oncology: Molecular Biology and Pathogenesis. *J Clin*440 *Med*. 2017;6(12):E111. doi:10.3390/jcm6120111
- de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable
 to infections in 2018: a worldwide incidence analysis. *Lancet Glob Health*. 2020;8(2):e180e190. doi:10.1016/S2214-109X(19)30488-7
- Neves AM, Thompson G, Carvalheira J, et al. Detection and quantitative analysis of human
 herpesvirus in pilocytic astrocytoma. *Brain Res.* 2008;1221:108-114.
 doi:10.1016/j.brainres.2008.05.009
- Chauvin C, Suh M, Remy C, Benabid AL. Failure to detect viral genomic sequences of three
 viruses (herpes simplex, simian virus 40 and adenovirus) in human and rat brain tumors. *Ital J Neurol Sci.* 1990;11(4):345-357. doi:10.1007/BF02335937

- 450 9. Cobbs CS, Harkins L, Samanta M, et al. Human cytomegalovirus infection and expression
 451 in human malignant glioma. *Cancer Res.* 2002;62(12):3347-3350.
- Wrensch M, Weinberg A, Wiencke J, et al. Does Prior Infection with Varicella-Zoster Virus
 Influence Risk of Adult Glioma? *Am J Epidemiol.* 1997;145(7):594-597.
 doi:10.1093/oxfordjournals.aje.a009155
- 455 11. Strojnik T, Duh D, Lah TT. Prevalence of Neurotropic Viruses in Malignant Glioma and Their
 456 Onco-Modulatory Potential. *In Vivo*. 2017;31(2):221-230. doi:10.21873/invivo.11049
- 457 12. Bondy ML, Scheurer ME, Malmer B, et al. Brain tumor epidemiology: Consensus from the
 458 Brain Tumor Epidemiology Consortium. *Cancer*. 2008;113(S7):1953-1968.
 459 doi:10.1002/cncr.23741
- 460 13. Amirian ES, Scheurer ME, Zhou R, et al. History of chickenpox in glioma risk: a report from
 461 the glioma international case–control study (GICC). *Cancer Med.* 2016;5(6):1352-1358.
 462 doi:10.1002/cam4.682
- 463 14. Kofman A, Marcinkiewicz L, Dupart E, et al. The roles of viruses in brain tumor initiation and
 464 oncomodulation. *J Neurooncol*. 2011;105(3):451-466. doi:10.1007/s11060-011-0658-6
- Limam S, Missaoui N, Bdioui A, et al. Investigation of simian virus 40 (SV40) and human JC,
 BK, MC, KI, and WU polyomaviruses in glioma. *J Neurovirol*. 2020;26(3):347-357.
 doi:10.1007/s13365-020-00833-4
- 468 16. Egan KM, Kim Y, Bender N, et al. Prospective investigation of polyomavirus infection and
 469 the risk of adult glioma. *Sci Rep.* 2021;11(1):9642. doi:10.1038/s41598-021-89133-3

- 470 17. Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR. Genetic and molecular epidemiology
 471 of adult diffuse glioma. *Nat Rev Neurol*. 2019;15(7):405-417. doi:10.1038/s41582-019-0220472 2
- 18. Eckel-Passow JE, Drucker KL, Kollmeyer TM, et al. Adult diffuse glioma GWAS by molecular
- 474 subtype identifies variants in *D2HGDH* and *FAM20C*. *Neuro-Oncol*. 2020;22(11):1602-1613.
- 475 doi:10.1093/neuonc/noaa117
- 476 19. Volpin F, Casaos J, Sesen J, et al. Use of an anti-viral drug, Ribavirin, as an anti-477 glioblastoma therapeutic. *Oncogene*. 2017;36(21):3037-3047. doi:10.1038/onc.2016.457
- 478 20. Stragliotto G, Pantalone MR, Rahbar A, Bartek J, Söderberg-Naucler C. Valganciclovir as
 479 Add-on to Standard Therapy in Glioblastoma Patients. *Clin Cancer Res.* 2020;26(15):4031-
- 480 4039. doi:10.1158/1078-0432.CCR-20-0369
- Piper K, Foster H, Gabel B, Nabors B, Cobbs C. Glioblastoma Mimicking Viral Encephalitis
 Responds to Acyclovir: A Case Series and Literature Review. *Front Oncol.* 2019;9:8.
 doi:10.3389/fonc.2019.00008
- 484 22. Besson C, Amiel C, Le-Pendeven C, et al. Strong Correlations of Anti–Viral Capsid Antigen
 485 Antibody Levels in First-Degree Relatives from Families with Epstein-Barr Virus–Related
 486 Lymphomas. *J Infect Dis.* 2009;199(8):1121-1127. doi:10.1086/597424
- 487 23. Kenney AD, Dowdle JA, Bozzacco L, et al. Human Genetic Determinants of Viral Diseases.
 488 Annu Rev Genet. 2017;51(1):241-263. doi:10.1146/annurev-genet-120116-023425
- 489 24. Venkataraman T, Valencia C, Mangino M, et al. *Antiviral Antibody Epitope Selection Is a*490 *Heritable Trait.* Genetics; 2021. doi:10.1101/2021.03.25.436790

- 491 25. Tay RE, Richardson EK, Toh HC. Revisiting the role of CD4+ T cells in cancer
 492 immunotherapy—new insights into old paradigms. *Cancer Gene Ther.* 2021;28(1-2):5-17.
 493 doi:10.1038/s41417-020-0183-x
- 494 26. Shiina T, Hosomichi K, Inoko H, Kulski JK. The HLA genomic loci map: expression, 495 interaction, diversity and disease. *J Hum Genet*. 2009;54(1):15-39. doi:10.1038/jhg.2008.5
- 496 27. Bateman AC, Howell WM. Human leukocyte antigens and cancer: is it in our genes? J
 497 Pathol. 1999;188(3):231-236. doi:10.1002/(SICI)1096-9896(199907)188:3<231::AID-
 498 PATH325>3.0.CO;2-A
- 499 28. Gebe JA, Swanson E, Kwok WW. HLA Class II peptide-binding and autoimmunity: Gebe et
 500 al : HLA Class II peptide-binding and autoimmunity. *Tissue Antigens*. 2002;59(2):78-87.
 501 doi:10.1034/j.1399-0039.2002.590202.x
- 29. Zhang C, de Smith AJ, Smirnov IV, et al. Non-additive and epistatic effects of HLA
 polymorphisms contributing to risk of adult glioma. *J Neurooncol.* 2017;135(2):237-244.
 doi:10.1007/s11060-017-2569-7
- 30. Kachuri L, Francis SS, Morrison ML, et al. The landscape of host genetic factors involved in
 immune response to common viral infections. *Genome Med.* 2020;12(1):93.
 doi:10.1186/s13073-020-00790-x
- 31. Melin BS, Barnholtz-Sloan JS, Wrensch MR, et al. Genome-wide association study of glioma
 subtypes identifies specific differences in genetic susceptibility to glioblastoma and nonglioblastoma tumors. *Nat Genet*. 2017;49(5):789-794. doi:10.1038/ng.3823

medRxiv preprint doi: https://doi.org/10.1101/2021.09.13.21263349; this version posted November 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 32. Wrensch M, Jenkins RB, Chang JS, et al. Variants in the CDKN2B and RTEL1 regions are
 associated with high-grade glioma susceptibility. *Nat Genet*. 2009;41(8):905-908.
 doi:10.1038/ng.408
- 514 33. Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma Groups Based on 1p/19q, *IDH*
- 515 , and *TERT* Promoter Mutations in Tumors. *N Engl J Med.* 2015;372(26):2499-2508.
- 516 doi:10.1056/NEJMoa1407279
- 34. Jenkins RB, Wrensch MR, Johnson D, et al. Distinct germ line polymorphisms underlie
 glioma morphologic heterogeneity. *Cancer Genet*. 2011;204(1):13-18.
 doi:10.1016/j.cancergencyto.2010.10.002
- Subsets and Pathways of Progression in Diffuse Glioma. *Cell*. 2016;164(3):550-563.
 doi:10.1016/j.cell.2015.12.028
- 36. Alexander DH, Lange K. Enhancements to the ADMIXTURE algorithm for individual ancestry
 estimation. *BMC Bioinformatics*. 2011;12(1):246. doi:10.1186/1471-2105-12-246
- 37. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM. Robust relationship
 inference in genome-wide association studies. *Bioinforma Oxf Engl.* 2010;26(22):28672873. doi:10.1093/bioinformatics/btq559
- 38. Jia X, Han B, Onengut-Gumuscu S, et al. Imputing Amino Acid Polymorphisms in Human
 Leukocyte Antigens. Tang J, ed. *PLoS ONE*. 2013;8(6):e64683.
 doi:10.1371/journal.pone.0064683

- 531 39. Bi W, Fritsche LG, Mukherjee B, Kim S, Lee S. A Fast and Accurate Method for Genome-
- 532 Wide Time-to-Event Data Analysis and Its Application to UK Biobank. *Am J Hum Genet*.
- 533 2020;107(2):222-233. doi:10.1016/j.ajhg.2020.06.003
- 534 40. Phan AT, Fernandez SG, Somberg JJ, Keck KM, Miranda JL. Epstein–Barr virus latency
- 535 type and spontaneous reactivation predict lytic induction levels. *Biochem Biophys Res*
- 536 *Commun.* 2016;474(1):71-75. doi:10.1016/j.bbrc.2016.04.070
- 537 41. Epstein MA, Achong BG, Barr YM. Virus Particles In Cultured Lymphoblasts From Burkitt's
 538 Lymphoma. *The Lancet*. 1964;283(7335):702-703. doi:10.1016/S0140-6736(64)91524-7
- 539 42. Akhtar S, Vranic S, Cyprian FS, Al Moustafa AE. Epstein–Barr Virus in Gliomas: Cause,
- 540 Association, or Artifact? *Front Oncol.* 2018;8:123. doi:10.3389/fonc.2018.00123
- 43. Germini D, Sall FB, Shmakova A, et al. Oncogenic Properties of the EBV ZEBRA Protein.
 542 *Cancers*. 2020;12(6):1479. doi:10.3390/cancers12061479
- 543 44. Chang Y, Moore PS. Merkel cell carcinoma: a virus-induced human cancer. *Annu Rev*544 *Pathol.* 2012;7:123-144. doi:10.1146/annurev-pathol-011110-130227
- 545 45. Kwun HJ, Chang Y, Moore PS. Protein-mediated viral latency is a novel mechanism for
- 546 Merkel cell polyomavirus persistence. Proc Natl Acad Sci U S A. 2017;114(20):E4040-
- 547 E4047. doi:10.1073/pnas.1703879114
- 548
- 549
- 550
- 551
- 552

It is made available under a CC-BY-NC-ND 4.0 International license .

553 Table 1: Clinical and molecular summary of the three case-control datasets

554

	UCSF-Mayo Cases N=1973	GICC Controls N=1859	AGS i370 Cases N=659	AGS i370 Controls N=586	TCGA Cases N=786	WTCCC Controls N=5711
Age						
<40	983 (50%)	538 (29%)	101 (15%)	85 (15%)	213 (27%)	0 (0%)
40-59	476 (24%)	555 (30%)	329 (50%)	252 (43%)	279 (36%)	0 (0%)
>= 60	514 (26%)	766 (41%)	229 (35%)	249 (42%)	245 (31%)	0 (0%)
Missing	0 (0%)	0 (0%)	0 (0%)	0 (0%)	49 (6%)	5711 (100%)
Sex						
Female	822 (42%)	744 (40%)	229 (35%)	280 (48%)	328 (42%)	2819 (49%)
Male	1151 (58%)	1115 (60%)	430 (65%)	306 (52%)	458 (58%)	2892 (51%)
IDH mutation status						
Mutant	588 (30%)	NA	111 (17%)	NA	375 (48%)	NA
Wild type	699 (35%)	NA	416 (63%)	NA	364 (46%)	NA
Missing	686 (35%)	NA	132 (20%)	NA	47 (6%)	NA
Molecular subtype based on IDH mutation and 1p/19q codeletion						
MT-codel	244 (12%)	NA	9 (1%)	NA	143 (18%)	NA
MT-noncodel	291 (15%)	NA	94 (14%)	NA	230 (29%)	NA
WT-noncodel	507 (26%)	NA	416 (63%)	NA	357 (46%)	NA
Missing/other	905 (47%)	NA	140 (22%)	NA	56 (7%)	NA

555NA: not applicable to controls

557 **Table 2: Summary of available cases and events for survival analyses**

558

	UCSF-Mayo		TCGA		AGS i370	
Molecular Subtype	Cases	Events	Cases	Events	Cases	Events
Glioma	1973	1218	786	310	659	592
IDH mutated	588	201	375	50	111	74
1p/19q codeleted	244	64	143	13	9	1
1p/19q non-codeleted	291	117	230	36	94	69
IDH wild type	699	594	364	228	416	402
1p/19q non-codeleted	507	458	357	224	416	402

559 560

9 Study/subtype combinations with less than 50 cases or 20 events were not utilized in the meta-analysis of survival associations.

560 Indentation indicates subtype is further subset of the above

It is made available under a CC-BY-NC-ND 4.0 International license .

561 **Figure 1: Summary of data processing and analysis**

562 Our analysis consisted of three glioma case-control datasets. The first dataset (purple) 563 included 786 glioma cases from The Cancer Genome Atlas (TCGA) genotyped on the Affymetrix 6.0 array and cancer-free controls assembled from two Wellcome Trust Case Control Consortium 564 565 (WTCCC) studies genotyped using the Affymetrix 6.0 array: 2,917 controls from the 1958 British 566 Birth cohort and 2,794 controls from the UK Blood Service control group. The second dataset (vellow) included 659 cases and 586 controls from the University of California, San Francisco 567 568 (UCSF) Adult Glioma Study (AGS) genotyped on the Illumina HumanHap370duo panel³². The 569 third set (blue) included 1973 cases from the Mayo Clinic and UCSF AGS and 1859 controls from 570 the Glioma International Case-Control Study (GICC) who were genotyped on the Illumina OncoArray, as previously described^{18,31-34}. The three resulting case-control datasets were 571 572 processed through quality controls as described in the main text and imputed using the TOPMed 573 imputation server. SNP2HLA was used to impute HLA alleles from SNP data. Risk and survival 574 analysis were performed separately on each study's imputed HLA alleles, on multiple glioma 575 molecular subtypes, and a fixed-effects meta analysis was performed to aggregate results. 576 Separately, genetic reactivity scores to 5 viral antigens were created using previously published 577 GWAS data. Cases and controls across the 3 studies were then assessed a genetically predicted 578 antibody reactivity score (GRS) to each of the 5 antigens. Risk and survival analysis were 579 performed separately on each study using each GRS score as a predictor, with results aggregated 580 using a fixed effects inverse variance weighted meta analysis for each subset of glioma patients 581 and controls based on molecular subtype.

582

583 Figure 2: GRS correlations within the UCSF-Mayo cases and controls

584 Pearson correlations between genetically predicted antigen responses (via GRS) as 585 computed in the UCSF-Mayo glioma cases and controls. Values were printed in each block if and 586 only if the associated correlation test p-value was less than 0.01.

587

588 Figure 3: Significant GRS-glioma subtype risk association meta-analysis

589 forest plots

590 Forest plot meta-analysis results of GRS-glioma risk associations which were at least 591 nominally statistically significant (p <0.05). Response to antigens EBV ZEBRA, MCV and EBV 592 EBNA had associations which reached this threshold. Results are reported as odds ratios, along 593 with 95% confidence intervals. Briefly, each header indicates the studied viral antigen GRS, within 594 are its association with molecular glioma subtypes reported with p<0.05, and the 95% confidence 595 interval of each study-specific effect. The diamond visualizes the 95% confidence interval for the 596 fixed effect (FE) meta-analysis across all 3 studies. Each meta-analysis was tested for between-597 study heterogeneity (Q statistic), with p<0.05 indicating evidence of study-specific associations.

598 Figure 4: Nominal GRS-glioma subtype survival association meta-analysis

599 forest plots

Forest plot meta-analysis results of GRS-glioma survival associations which were at least 600 601 nominally statistically significant (p < 0.05). Genetically inferred response to antigens EBV ZEBRA, 602 MCV and EBV EBNA had associations which reached this threshold. Results are reported as 603 hazard ratios, along with 95% confidence intervals. Briefly, each header indicates the studied viral 604 antigen GRS, within are its association with molecular glioma subtypes reported with p<0.05, and 605 the 95% confidence interval of each study-specific effect. The diamond visualizes the 95% 606 confidence interval for the fixed effect (FE) meta-analysis across included studies. Studies which 607 had an insufficient number of cases/events in a subtype were not included in the meta-analysis. 608 Each meta-analysis (where more than one study was included) was tested for between-study 609 heterogeneity (Q statistic), with p<0.05 indicating evidence of study-specific associations.

610

Figure 5: Kaplan Meier curves for significant GRS_{EBNA} - glioma molecular

612 subtype associations

613 Kaplan-Meier curves for subtypes where GRS_{EBNA} was nominally associated with subtype 614 specific glioma survival differences (p <0.05 via Cox regression). The second and third plots are 615 distinct partitions of the IDH mutated subgroup. To visualize, unnormalized GRS scores across the included studies were binned based on the case-specific 80th percentile score in the UCSF-616 617 Mayo dataset. P-values included on each plot are results of a log-rank test for difference between 618 the two curves. Below each set of curves provides the number of cases surviving beyond that 619 time point, for each of the two GRS groups. In all cases, the glioma cases with higher GRS score 620 for EBV EBNA had visually improved survival outcomes compared to the bottom 80%.









